30 March 2021
A survey led by the University of Oxford has found that most people in high-income countries support donating some of their country’s COVID-19 vaccine supplies to low-income nations who would otherwise struggle to gain access. The findings are published today in Nature Medicine.
Researchers conducted an anonymous online survey which had over 8,000 respondents across seven high-income countries (Australia, Canada, France, Italy, Spain, UK and the USA). The survey was carried out between 24 November and 28 December 2020, when an effective vaccine was expected to soon be available.
The study’s main findings were:
- For each country assessed, the number of people who supported donating vaccines was at least double those who did not. Support for donating vaccines ranged from 48–56%, whilst 15–26% did not support donating vaccines and 22–28% were undecided.
- Of those who supported vaccine donations, most (73–81%) favoured an amount greater than or equal to 10% of their country’s doses.
- When asked how much they agreed with three prioritisation principles for global vaccine distribution, the highest-ranking principle for each country was need, with average agreement ranging from 70–80 (where 0 means very much disagree and 100 means very much agree). This was followed by prioritising countries which could not afford to buy vaccines otherwise (62–70 average agreement), and finally whether the country itself had developed the vaccine (28–58 average agreement).
The COVAX collaboration aims to ensure that all countries have equal access to COVID-19 vaccines, and competes with high-income countries to acquire doses. Nevertheless, some low-income countries may need to wait until at least next year before even the most vulnerable 20% of their populations are vaccinated.1 This is due in part to some high-income countries pre-purchasing vaccine supplies that exceed their population size. For instance, the USA has reserved more than 1.2 billion doses2, but has a population of around 331 million.
The results of this study indicate that individuals in high-income countries would generally support donating COVID-19 vaccines to low-income countries. This has been done for previous pandemics, including the 2009 Swine Flu outbreak.
Lead researcher Professor Philip Clarke, from the University of Oxford’s Nuffield Department of Population Health, said: ‘Redistributing vaccine supplies from high-income countries would have global benefits. It would reduce the risk of the emergence and spread of new variants and benefit the economy, both globally and in donor countries. In contrast, the economic cost of vaccine nationalism is potentially high. The world’s economy is highly interconnected and as long as the virus is not under control everywhere, there will be a huge cost to the global economy – up to $1.2 trillion per year according to some estimates.’
Notes to editors:
The study is published today in Nature Medicine: https://www.nature.com/articles/s41591-021-01322-9
For enquiries and interview requests, contact Gen Juillet, Media Relations Manager, University of Oxford, email@example.com
The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and the COVID-19 Oxford Vaccine Trial. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. We acknowledge the support of the Office of the Dean of the Faculty of Arts & Science at the University of Toronto. Jorge Friedman received funding from the University of Santiago project Dicyt USA1899. Alessia Melegaro acknowledges support from the Italian Ministry of Education Progetti di Rilevante Interesse Nazionale (PRIN), grant number 20177BRJXS. Mara Violato receives funding from the National Institute for Health Research (NIHR) Applied Research Collaboration Oxford and Thames Valley at Oxford Health NHS Foundation Trust. The survey study was approved by the University of Oxford Medical Sciences Interdivisional Research Ethics Committee (Approval ID: R72328/RE001).
- Why a pioneering plan to distribute COVID vaccines equitably must succeed. Editorial, Nature: 589, 170 (2021). https://www.nature.com/articles/d41586-021-00044-9
- Duke Global Health Innovation Center. Launch and Scale Speedometer. Duke University. https://launchandscalefaster.org/COVID-19 [Accessed 16 March 2020].
The University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
The Nuffield Department of Population Health (NDPH) is a world-leading research institute, based at the University of Oxford that investigates the causes and prevention of disease. NDPH has over 750 staff, students and academic visitors working in a number of world-renowned population health research groups, including the Cancer Epidemiology Unit (CEU), Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), the Health Economics Research Centre (HERC), and the MRC Population Health Research Unit (MRC PHRU), and other groups working on perinatal epidemiology, public health, ethics and health record linkage. It is also a key partner in the Oxford University Big Data Institute. For further information, please visit www.ndph.ox.ac.uk.